288 related articles for article (PubMed ID: 33847848)
1. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
Wu Q; Bai B; Tian C; Li D; Yu H; Song B; Li B; Chu X
Cardiovasc Drugs Ther; 2022 Jun; 36(3):511-524. PubMed ID: 33847848
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
[TBL] [Abstract][Full Text] [Related]
3. Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
Barachini S; Ghelardoni S; Varga ZV; Mehanna RA; Montt-Guevara MM; Ferdinandy P; Madonna R
Vascul Pharmacol; 2023 Dec; 153():107223. PubMed ID: 37678516
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.
Touyz RM; Herrmann J
NPJ Precis Oncol; 2018; 2():13. PubMed ID: 30202791
[TBL] [Abstract][Full Text] [Related]
5. Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.
Cohen JB; Brown NJ; Brown SA; Dent S; van Dorst DCH; Herrmann SM; Lang NN; Oudit GY; Touyz RM;
Hypertension; 2023 Mar; 80(3):e46-e57. PubMed ID: 36621810
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxic effects of angiogenesis inhibitors.
Dobbin SJH; Petrie MC; Myles RC; Touyz RM; Lang NN
Clin Sci (Lond); 2021 Jan; 135(1):71-100. PubMed ID: 33404052
[TBL] [Abstract][Full Text] [Related]
7. The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.
Scott JM; Lakoski S; Mackey JR; Douglas PS; Haykowsky MJ; Jones LW
Oncologist; 2013; 18(2):221-31. PubMed ID: 23335619
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Magnetic Resonance Imaging Findings in Human Epidermal Growth Factor Receptor 2-Targeted Therapy-Related Cardiotoxicity.
Şener YZ; Ardalı Düzgün S; Hazırolan T; Tokgözoğlu L
Anatol J Cardiol; 2023 Dec; 27(12):E38-E39. PubMed ID: 38031670
[No Abstract] [Full Text] [Related]
9. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors.
Jin Y; Xu Z; Yan H; He Q; Yang X; Luo P
Front Pharmacol; 2020; 11():891. PubMed ID: 32595510
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity associated with targeted cancer therapies.
Chen ZI; Ai DI
Mol Clin Oncol; 2016 May; 4(5):675-681. PubMed ID: 27123262
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.
Varricchi G; Ameri P; Cadeddu C; Ghigo A; Madonna R; Marone G; Mercurio V; Monte I; Novo G; Parrella P; Pirozzi F; Pecoraro A; Spallarossa P; Zito C; Mercuro G; Pagliaro P; Tocchetti CG
Front Physiol; 2018; 9():167. PubMed ID: 29563880
[TBL] [Abstract][Full Text] [Related]
12. Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments.
Audebrand A; Désaubry L; Nebigil CG
Front Cardiovasc Med; 2019; 6():194. PubMed ID: 32039239
[TBL] [Abstract][Full Text] [Related]
13. A simple and rapid pre-clinical in vivo model reveals comparative cardiotoxicity profiles of kinase inhibitors.
Mohammed QKQ; Banu N; Police SR; Palakurthy S; Thota S; Padamati SP; Puligundla KC; Amanchi NR; Kancha RK
Toxicol Appl Pharmacol; 2024 May; 486():116944. PubMed ID: 38677603
[TBL] [Abstract][Full Text] [Related]
14. Proteomic cellular signatures of kinase inhibitor-induced cardiotoxicity.
Xiong Y; Liu T; Chen T; Hansen J; Hu B; Chen Y; Jayaraman G; Schürer S; Vidovic D; Goldfarb J; Sobie EA; Birtwistle MR; Iyengar R; Li H; Azeloglu EU
Sci Data; 2022 Jan; 9(1):18. PubMed ID: 35058449
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management.
Barachini S; Buda G; Petrini I
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541800
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of chemotherapy and targeted agents.
Mudd TW; Khalid M; Guddati AK
Am J Cancer Res; 2021; 11(4):1132-1147. PubMed ID: 33948350
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies.
Gomez JA
Am Heart J Plus; 2022 May; 17():100144. PubMed ID: 38559889
[TBL] [Abstract][Full Text] [Related]
18. Reply to Letter to the Editor: 'Cardiotoxicity Associated with Antihuman Epidermal Growth Factor Receptor-2 Therapy: Particular Aspects of a Specific Phenomenon'.
Şener YZ; Ardalı Düzgün S; Hazırolan T; Tokgözoğlu L
Anatol J Cardiol; 2024 Feb; 28(2):130-131. PubMed ID: 38295234
[No Abstract] [Full Text] [Related]
19. Multi-Target Drugs for Blood Cancer in the Elderly: Implications of Damage and Repair in the Cardiovascular Toxicity.
Madonna R
Front Physiol; 2021; 12():792751. PubMed ID: 34950060
[No Abstract] [Full Text] [Related]
20. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
